Zacks.com on MSN13h
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following ...
Business Insider23h
Promising Potential of Aclaris Therapeutics’ BSI-045B and Pipeline Elevates Buy Rating
Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept ...
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
BioWorld2d
Biosion sells antibody rights to Aclaris in $940M deal
Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion ...
Biosion Inks Exclusive Deal With Aclaris For Worldwide Rights To BSI-045B And BSI-502
Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...